Results 31 to 40 of about 2,106 (155)
Natural form of noncytolytic flexible human Fc as a long-acting carrier of agonistic ligand, erythropoietin. [PDF]
PLoS ONE, 2011 Human IgG1 Fc has been widely used as a bioconjugate, but exhibits shortcomings, such as antibody- and complement-mediated cytotoxicity as well as decreased bioactivity, when applied to agonistic proteins.
Se Jin Im +16 more
doaj +1 more source
American Journal of Hematology, Volume 101, Issue 4, Page 784-793, April 2026.A novel erythropoietin (EPO) promoter mutation (c.‐136 G>A) causes autosomal dominant erythrocytosis via non‐renal expression of EPO. ABSTRACT We previously reported a five‐generation kindred with autosomal dominant erythrocytosis associated with a novel germline promoter variant in the erythropoietin (EPO) gene (EPO c.‐136 G>A).
Lucie Lanikova +10 more
wiley +1 more source
Biopharmaceuticals for Cancer Treatment: An Update
Cancer Medicine, Volume 15, Issue 4, April 2026.ABSTRACT Cancer is one of the most debilitating diseases, causing profound physical and psychological impacts on patients. The global number of cancer patients has been steadily rising over the last few decades. The development of effective cancer therapies remains the primary focus in life science research, requiring a precise understanding of ...
Anupom Deb Nath +6 more
wiley +1 more source
Nephrology, Volume 31, Issue 4, April 2026.ABSTRACT There is limited evidence to guide optimal frequency of surveillance bloodwork for haemodialysis patients. In September 2023, surveillance bloodwork frequency was reduced from monthly to 6‐weekly across 4 Illawarra‐Shoalhaven dialysis units.
Daniel Hirsch +10 more
wiley +1 more source
Український Журнал Нефрології та Діалізу, 2014 the article describes approaches to cost optimization of anemia treatment in CKD–VDst. patients by comparison of costs in phase correction and support treatment with long action ESA in patients on HD and HDF. Aims.
M. Kolesnyk +4 more
doaj +1 more source
Pharmacoepidemiology and Drug Safety, Volume 35, Issue 3, March 2026.ABSTRACT Purpose Adverse drug reactions (ADRs) present significant obstacles for healthcare systems, impacting both patient safety and the effectiveness of treatments. Despite this, there is a scarcity of research on ADR reports in Sierra Leone, especially over long periods.
Isatu Jalloh +4 more
wiley +1 more source
Clinical Pharmacology &Therapeutics, Volume 119, Issue 2, Page 322-335, February 2026.Model‐informed drug development (MIDD) played a crucial role in the successful development and regulatory approval of daprodustat, a novel oral hypoxia‐inducible factor prolyl hydroxylase (HIF‐PHI) inhibitor aimed at treating anemia in chronic kidney disease patients.
Kelly M. Mahar +6 more
wiley +1 more source
Clinical and Translational Science, Volume 19, Issue 2, February 2026.ABSTRACT The Ministerial Ordinance on Good Post‐Marketing Study Practice for Drugs was amended by the Ministry of Health, Labour and Welfare (MHLW) in 2018 to clearly define post‐marketing database studies (DBS) as a measure of pharmacovigilance activities for approved medical products in Japan.
Suguru Okami +2 more
wiley +1 more source
Тонкие химические технологии, 2020 Objectives. We hereby describe an improvement of a previously developed quantification technique for polysorbate 80 in biopharmaceutical formulations (darbepoetin alfa and eculizumab) and report the validation of the new approach.Methods. Polysorbate was
A. S. Seregin +4 more
doaj +1 more source
Clinical Pharmacology &Therapeutics, Volume 119, Issue 1, Page 228-240, January 2026.Data science approaches have been increasingly implemented in healthcare big data to evaluate the safety and effectiveness of drugs. Association discovery is a data mining approach that finds potentially associated elements in high‐dimensional data. We present a novel implementation of the association discovery approach in longitudinal healthcare data ...
George S. Q. Tan +6 more
wiley +1 more source